Recursion Pharmaceuticals, Inc. vs Septerna, Inc. — Valuation Comparison 2026
Access all valuation models for RXRX vs SEPN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →SEPN scores higher with a 7.0/10 quality rating vs RXRX's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Recursion Pharmaceuticals, Inc. (RXRX) and Septerna, Inc. (SEPN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
RXRX currently trades at $3.44 with a QOC of 6.5/10, while SEPN trades at $31.05 with a QOC of 7.0/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).